| NCT05935332 | Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma | TERMINATED | PHASE2 | 2023-07-05 | 2024-06-21 | 2024-06-21 |
| NCT06087978 | Study of RPT193 in Healthy Adult Male Subjects | COMPLETED | PHASE1 | 2023-07-05 | 2023-10-12 | 2023-10-12 |
| NCT05399368 | An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis | TERMINATED | PHASE2 | 2022-06-07 | 2024-05-24 | 2024-05-24 |
| NCT04894994 | FLX475 in Combination With Ipilimumab in Advanced Melanoma | TERMINATED | PHASE2 | 2021-09-03 | 2022-09-13 | 2022-09-13 |
| NCT04271514 | A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis | COMPLETED | PHASE1 | 2019-08-12 | 2021-04-26 | 2021-04-26 |
| NCT03674567 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab | COMPLETED | PHASE1, PHASE2 | 2018-09-25 | 2024-12-31 | 2024-12-31 |
| NCT02335814 | First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | TERMINATED | PHASE1 | 2015-04-08 | 2017-05-03 | 2017-05-03 |